These nanoparticles killed ovarian cancer cells mainly independently of p53 mutation status (with the exception of p53 R273H-mutated ovarian cancer cells, which did not respond) in vitro while inducing a much smaller effect in normal mouse fibroblasts, suggesting their potential as a general ovarian cancer therapy [75,131]. Here, TP53 is linked to ovarian carcinoma.